The valuation premium relative to peers like Teva suggests that investors are assigning significant weight to the company's interchangeable biosimilar pipeline rather than current cash flows. This multiple warrants caution, as any delay in regulatory approvals or PBM formulary placement could lead to a sharp contraction in valuation multiples.

The inability to consistently compound returns on invested capital reflects the heavy burden of R&D and the high fixed-cost nature of the Reykjavik facility. Until the company achieves sustained commercial scale, ROIC will likely remain suppressed by the ongoing requirement to fund clinical trials and manufacturing overhead.

The elevated DIO and DSO figures indicate that inventory is not moving through the supply chain as quickly as required to support a lean operating model. Investors should monitor whether these inefficiencies are structural or merely a temporary byproduct of launching new biosimilar products into competitive markets.

The volatility in liquidity ratios suggests that the company's cash position is highly sensitive to the timing of milestone receipts and the high cash burn associated with its manufacturing operations. This lack of liquidity stability may necessitate further external financing, potentially leading to additional shareholder dilution.